Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer

NCT03544125 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT03544125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03544125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
May 3, 2018
Completion date
November 18, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, estrogen receptor negative, her2/neu negative, progesterone receptor negative, prognostic stage iv breast cancer ajcc v8, triple-negative breast carcinoma